Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Fractional Laser as Treatment Option for Various Pigment Disorders (fractional-2)

This study has been completed.
Sponsor:
Information provided by:
Netherlands Institute for Pigment Disorders
ClinicalTrials.gov Identifier:
NCT01083498
First received: March 8, 2010
Last updated: NA
Last verified: March 2010
History: No changes posted

March 8, 2010
March 8, 2010
March 2009
January 2010   (final data collection date for primary outcome measure)
Physician's global assessment [ Time Frame: T0, 3 and 6 months follow-up ] [ Designated as safety issue: Yes ]
Improvement of hyperpigmentation was assessed by an independent blinded dermatologist. The results were scored on a scale from zero to six (0: total clearance (100% improvement), 1: almost total clearance (90-99% improvement), 2: distinct clearance (75-89% improvement) 3: moderate clearance (50-74% improvement) 4: mild clearance (25-49% improvement) 5: no change, 6: worsening of hyperpigmentation).
Same as current
No Changes Posted
  • L-value [ Time Frame: T0, 3 and six months follow-up ] [ Designated as safety issue: Yes ]
    Improvement of hyperpigmentation was assessed by color measurement through reflectance spectroscopy (Microflash 200 d, Datacolor International, Lawrenceville, GA). This instrument, with an aperture of 4 mm, determines color by measuring the intensity of reflected light of particular wavelengths. In this study, the obtained L value, reflecting the lightness of the measured area of skin, was used.
  • Melanin index [ Time Frame: T0, 3 and 6 months follow-up ] [ Designated as safety issue: Yes ]
    Melanin index was measured using a spectrometer (Derma-Spectrometer, Cortex Technology ApS, Hadsund, Denmark) in order to assess changes in the amount of dermal and epidermal melanin.
  • Patient's global assessment [ Time Frame: 3 and 6 months follow-up ] [ Designated as safety issue: Yes ]
    Patients were asked to score the improvement of hyperpigmentation on a visual analogue scale (VAS) from 0 to 10 (Patient's Global Assessment, PGA) at all follow-up moments.
  • Patient's satisfaction [ Time Frame: 3 and 6 months follow-up ] [ Designated as safety issue: Yes ]
    Patient's satisfaction was scored on a visual analogue scale (VAS) from 0 to 10.
  • Histopathologic assessment [ Time Frame: 3 months follow-up ] [ Designated as safety issue: No ]
    In order to evaluate for microscopic and ultrastructural treatment induced changes, 2 mm punch biopsies were taken from all patients at three months follow-up. Biopsies were taken from the optical centre of both treated and control site. All biopsy specimens were split for processing for light microscopy. .... was assessed by an independent blinded pathologist.
Same as current
Not Provided
Not Provided
 
Fractional Laser as Treatment Option for Various Pigment Disorders
Ablative Fractional Laser Therapy as Treatment for Becker's Nevus; a Pilot Study

The purpose of this study is to determine whether the use of ablative fractional laser is effective in the treatment of Becker's nevus.

Becker's nevus (BN) is an uncommon pigment disorder of the epidermis characterized by increased pigmentation, a slightly elevated, verrucous surface of the affected skin and sometimes hyperpigmentation. No effective treatment is available. Several laser modalities have been applied in the treatment of Becker's nevus in uncontrolled studies with varying results. Recently, fractional laser therapy was suggested as treatment option for Becker's nevus. In fractional laser therapy, microscopic columns of skin are coagulated or ablated, leaving the surrounding tissue intact, which enhances healing of the treated skin. In this study, the efficacy and safety of ablative fractional laser therapy was assessed in the treatment of Becker's nevus.

Interventional
Phase 2
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Single Blind (Investigator)
Primary Purpose: Treatment
Pigmentation Disorder
Device: Ablative fractional laser therapy
10,600 nm ablative fractional laser Irradiance: 10 mJ/microbeam. Coverage: 35-45%. Number of treatment sessions: 3
Other Name: Fraxel re:pair, Solta Medical Inc., Hayward, CA
  • Experimental: Ablative fractional laser

    In each patient, a square test region of 5-10 cm2 was treated with ablative fractional laser in three sessions in combination with intermittent topical bleaching with triple topical therapy (hydroquinone 5%, tretinoin 0.05%, triamcinolone acetonide 0.1% cream) to prevent laser-induced postinflammatory hyperpigmentation.

    Note: this study had a split-lesion design. In each patient, two test regions were randomized to receive either ablative fractional laser therapy or no treatment.

    Intervention: Device: Ablative fractional laser therapy
  • No Intervention: Control

    In each patient, a square test region of 5-10 cm2 was treated with topical bleaching with triple topical therapy (hydroquinone 5%, tretinoin 0.05%, triamcinolone acetonide 0.1% cream)alone (to allow comparison of the regions).

    Note: this study had a split-lesion design. In each patient, two test regions were randomized to receive either ablative fractional laser therapy or no treatment.

Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
11
January 2010
January 2010   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Becker nevus
  • Subjects attending the outpatient department of the Netherlands Institute for Pigment Disorders
  • Age at least 18 years
  • Subject is willing and able to give written informed consent

Exclusion Criteria:

  • use of bleaching creams during the past six weeks
  • history of keloid
  • active eczema
  • suspected hypersensitivity to lidocaine or triple therapy
  • use of isotretinoin in the past six months
  • high exposure of the lesion to sunlight or UV light (UVA or UVB).
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
NCT01083498
fractional-2
No
A Wolkerstorfer, MD PhD, Netherlands Institute for Pigment Disorders
Netherlands Institute for Pigment Disorders
Not Provided
Not Provided
Netherlands Institute for Pigment Disorders
March 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP